Skip to main content
OpenTrials
Completed

NCT Number: NCT05123248

Integrating the Use of Calibration-Free Continuous Monitoring for Pregnancy Glucose Profiling: I-Profile Study

This study aims to test the following hypotheses in a longitudinal, observational study in pregnant women who will be randomized to received either a Blinded or Unblinded CGM sensor and followed-up 6-12 weeks after delivery:

1. CF-CGM device is well tolerable and accurate for glucose level monitoring in women with a normal pregnancy. 2. CF-CGM device is well tolerable and acceptable in women with GDM who are required intensive glucose monitoring on a daily basis during pregnancy and even after delivery. 3. There are trimester-specific glucose profiles observed in the whole pregnancy. 4. Pregnancies complicated with GDM would show a specific glucose profile that is different from non-GDM pregnancies (e.g. greater daily fluctuations, more episodes and longer duration of glucose spikes after meal). 5. There is a good correlation between one-day glucose profile and OGTT test at 24-31 weeks gestation GDM screening. 6. Pre-GDM screening glucose profiles is predictive of GDM diagnosis at 24-31 weeks gestation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

KK Women's and Children's Hospital

Singapore, 229899

About this study

GDM affects 5-10% of pregnant women in Europe, while the prevalence in Asian populations is significantly higher at approximately 15-20%. However, the GDM screening approaches, timing and targeted population still varies greatly in clinical practice all over the world, which makes the prevalence of GDM difficult to compare universally. Since the early days of the 21st century, the continuous glucose monitoring system (CGM) has been used for constant evaluation of glucose levels by measuring interstitial glucose concentrations. It can potentially improve diabetes care if used carefully with proper understanding of the characteristics of this system.

This is longitudinal, observational and hospital-based study. A total of 500 pregnant women will be recruited with consent form completion after meeting our inclusion criteria. The recruited women will then be randomly assigned to a Blinded and Unblinded CGM device.

All pregnant women aged 21 and above who plan to be followed up throughout pregnancy and intend to deliver at KKH and currently attending KKH for antenatal consultation during their early trimester will be approached by study research personnel, and will be followed up from then onwards. If they agree to take part in the study, consent will be signed at the first trimester clinic visit.

All recruited subjects will be randomized to put on a Blinded or Unblinded CGM device for 14 days from the first trimester (9-13 weeks), 18-23 weeks, 24-31 weeks, and 32-33 weeks. If a pregnant subject is diagnosed with GDM using International association of diabetes and pregnancy study groups (IADPSG) guidelines at KKH at 24-31 weeks gestation, she will be required to wear the sensor continuously until 38 weeks gestation, and will be followed up for another 14 days at the 6-12 weeks postnatal period.

Data will be collected through questionnaires and clinical measurements. The questionnaires include socio-economic factors, medical histories, lifestyle factors, health status, and home environment. Bio-physical measurements will be obtained from anthropometric measurements of participants, human biological materials such as blood, are collected from the participants at their follow-up time points with the I-PROFILE study upon their consent.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who are Singapore citizens or Singapore Permanent Residents, and plan to be followed up throughout pregnancy and intend to deliver at KKH;
  • Aged 21 and above;
  • Singleton pregnancy

Exclusion criteria

  • Have serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days;
  • Patients who have any other chronic disease such as chronic kidney disease.
  • Unable to read or speak English

Treatment and study plan

Blinded Group

Device

Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.

Unblinded group

Device

Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.

Primary outcomes

  1. Gestational Diabetes Mellitus (GDM)

    Time frame: 24-31 weeks gestation

    Clinical outcomes of Gestational Diabetes Mellitus (GDM) development determined by oral glucose tolerance test

Secondary outcomes

  1. CGM summary metrics derived from extracted CGM glucose data

    Time frame: First trimester: 9-13 weeks, Second trimester: 18-23 weeks, 24-31 weeks, 32-33 weeks

    Glucose profiles extracted from the continous glucose monitoring (CGM) device

  2. Plasma glucose measures from OGTT

    Time frame: 24-31 weeks gestation

    Fasting, one hour and 2 hour glucose values obtained from OGTT

Other outcomes

  1. Applicability, acceptability, compliance of the blinded the CGM device use in a normal pregnancy.

    Time frame: At 32-33 weeks gestation

    Using a 10-item patient feedback survey

  2. Applicability, acceptability, compliance of the unblinded the CGM device use in a normal pregnancy.

    Time frame: At 32-33 weeks gestation

    Using a 14-item patient feedback survey

  3. Applicability, acceptability, compliance of the blinded CGM device use in a GDM pregnancy

    Time frame: 6-12 weeks postnatal

    Using 10-item patient feedback survey

  4. Applicability, acceptability, compliance of the unblinded CGM device use in a GDM pregnancy

    Time frame: 6-12 weeks postnatal

    Using a 14-item patient feedback survey

Sponsors and collaborators

Lead sponsor

KK Women's and Children's Hospital

Other Gov

Registry information

Acronym: I-Profile

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Nov 17, 2021
Registry last updated
Oct 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.